论文部分内容阅读
目的观察拉米夫定治疗活动性失代偿期乙型肝炎后肝硬化的疗效和安全性。方法选择活动性失代偿期乙型肝炎后肝硬化患者98例,其中治疗组50例用拉米夫定治疗,对照组48例不做任何抗病毒及免疫调节治疗,两组均常规使用护肝、对症治疗。结果治疗12个月后,治疗组临床症状、体征、生化学指标改善情况与对照组比较差异均有统计学意义(P<0.01),病毒学指标HBV-DNA阴转,差异有统计学意义(P<0.01)。结论拉米夫定治疗活动性失代偿期乙型肝炎后肝硬化可明显抑制乙肝病毒(HBV)复制,控制肝脏炎症,改善肝功能,降低并发症,缓解病情,降低病死率,且有较高安全性,值得进一步研究。
Objective To observe the efficacy and safety of lamivudine in the treatment of hepatic cirrhosis after active decompensated hepatitis B (HBV). Methods 98 patients with active decompensated hepatitis B after liver cirrhosis were selected. Among them, 50 patients in the treatment group were treated with lamivudine, while 48 patients in the control group were treated with anti-virus and immunomodulatory therapy. Liver, symptomatic treatment. Results After 12 months of treatment, the improvement of clinical symptoms, signs and biochemical indexes in the treatment group was statistically significant (P <0.01), and the virological index of HBV-DNA was negative in the treatment group (P <0.01) P <0.01). Conclusion Lamivudine treatment of active decompensated hepatitis B cirrhosis can significantly inhibit the replication of hepatitis B virus (HBV), control the liver inflammation, improve liver function, reduce complications, ease the disease, reduce mortality, and more High security, it is worth further study.